Korean pharma scandal deepens after disclosure in ICC case
A scandal in Korea over the mislabelling of a gene therapy treatment for osteoarthritis has intensified after it emerged in an ICC arbitration that the product’s developer was allegedly aware two years ago that its ingredients had changed.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.